Show simple item record

dc.contributor.authorLee, BP
dc.contributor.authorHarries, LW
dc.date.accessioned2022-05-13T09:46:35Z
dc.date.issued2021-11-29
dc.date.updated2022-05-12T13:19:26Z
dc.description.abstractSUMMARY: Skin aging is an outward manifestation of other cellular and molecular aging processes occurring elsewhere in the body. These processes are known collectively as the "hallmarks" of aging, which are a series of basic health maintenance mechanisms that fail over time. Cellular senescence is one of the most studied of the hallmarks of aging; senescent cells accumulate over time and are major drives of the aging process. Here, we discuss the impact of cellular senescence in the context of skin aging, and discuss the emerging landscape of interventions designed for their selective removal by targeted cell death (senolytics) or rejuvenation (senomorphics). We discuss the serotherapeutic strategies that are currently under investigation for systemic aging, which may bring eventual benefits for skin health. Next, we discuss a newly discovered hallmark of aging, dysregulated mRNA processing, which can be targeted for the senomorphic effect. Finally, we highlight a new modality for manipulation of disrupted mRNA processing, oligonucleotide therapeutics. The emerging field of senotherapeutics is set to revolutionize how we view and treat skin aging, and senotherapies are now poised to become a new class of skincare interventions.en_GB
dc.format.extent21S-26S
dc.format.mediumPrint
dc.identifier.citationVol. 148(6S), pp. 21S-26Sen_GB
dc.identifier.doihttps://doi.org/10.1097/PRS.0000000000008782
dc.identifier.urihttp://hdl.handle.net/10871/129603
dc.identifierORCID: 0000-0001-7791-8061 (Harries, Lorna W)
dc.identifierScopusID: 13805289700 (Harries, Lorna W)
dc.identifierResearcherID: D-2241-2014 | E-2369-2011 (Harries, Lorna W)
dc.language.isoenen_GB
dc.publisherLippincott, Williams & Wilkins / American Society of Plastic Surgeonsen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/34847094en_GB
dc.rights.embargoreasonUnder embargo until 29 November 2022 in compliance with publisher policyen_GB
dc.rights© 2021 American Society of Plastic Surgeons. This version is made available under the CC-BY-NC 4.0 license: https://creativecommons.org/licenses/by-nc/4.0/  en_GB
dc.titleSenotherapeutic drugs: A new avenue for skincare?en_GB
dc.typeArticleen_GB
dc.date.available2022-05-13T09:46:35Z
dc.identifier.issn0032-1052
exeter.place-of-publicationUnited States
dc.descriptionThis is the author accepted manuscript. The final version is available from Lippincott, Williams & Wilkins via the DOI in this recorden_GB
dc.identifier.eissn1529-4242
dc.identifier.journalPlastic and Reconstructive Surgeryen_GB
dc.relation.ispartofPlast Reconstr Surg, 148(6S)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/  en_GB
dcterms.dateAccepted2021
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2021-11-29
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-05-13T09:42:20Z
refterms.versionFCDAM
refterms.panelAen_GB
refterms.dateFirstOnline2021-11-29


Files in this item

This item appears in the following Collection(s)

Show simple item record

© 2021 American Society of Plastic Surgeons. This version is made available under the CC-BY-NC 4.0 license: https://creativecommons.org/licenses/by-nc/4.0/  
Except where otherwise noted, this item's licence is described as © 2021 American Society of Plastic Surgeons. This version is made available under the CC-BY-NC 4.0 license: https://creativecommons.org/licenses/by-nc/4.0/